Overview

Description

  • NatureRecombinant
  • SourceEscherichia coli
  • Amino Acid Sequence
    • SpeciesHuman
    • SequenceMMMHMDQQPKEICALVGFCDEVKEMPMQTLVPAKVASKNVIPALELVEPI KKH EVPAKSDVYCEVCEFLVKEVTKLIDNNKTEKEILDAFDKMCSKLP KSLSEECQ EVVDTYGSSILSILLEEVSPELVCSMLHLCSGTRLPALTV HVTQPKDGGFCEV CKKLVGYLDRNLEKNSTKQEILAALEKGCSFLPDP YQKQCDQFVAEYEPVLIE ILVEVMDPSFVCLKIGACPSAHKPLLGTEK CIWGPSYWCQNTETAAQCNAVEH CKRHVWN
    • Amino acids255 to 526

Specifications

Our Abpromise guarantee covers the use of ab93982 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications

    SDS-PAGE

  • FormLyophilised
  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Store at 4°C prior to reconstitution. Store at -80°C.

    Preservative: None
    Constituents: 0.5% Trehalose, 6M Urea, 100mM Sodium phosphate, 10mM Sodium chloride, pH 4.5

  • ReconstitutionReconstitute with 58 µl aqua dest.

General Info

  • Alternative names
    • A1 activator
    • Cerebroside sulfate activator
    • Co-beta-glucosidase
    • Component C
    • CSAct
    • Dispersin
    • GLBA
    • Glucosylceramidase activator
    • Proactivator polypeptide
    • Proactivator polypeptide precursor
    • Prosaposin
    • Prosaposin (sphingolipid activator protein 1)
    • prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy)
    • Protein A
    • Protein C
    • PSAP
    • SAP-1
    • SAP-2
    • SAP_HUMAN
    • SAP1
    • Saposin A
    • Saposin B
    • Saposin B Val
    • Saposin C
    • Saposin D
    • Saposin-D
    • Saposins
    • Sgp1
    • Sphingolipid activator protein 1
    • Sphingolipid activator protein 2
    • Sulfated glycoprotein 1
    • Sulfatide/GM1 activator
    see all
  • FunctionThe lysosomal degradation of sphingolipids takes place by the sequential action of specific hydrolases. Some of these enzymes require specific low-molecular mass, non-enzymic proteins: the sphingolipids activator proteins (coproteins).
    Saposin-A and saposin-C stimulate the hydrolysis of glucosylceramide by beta-glucosylceramidase (EC 3.2.1.45) and galactosylceramide by beta-galactosylceramidase (EC 3.2.1.46). Saposin-C apparently acts by combining with the enzyme and acidic lipid to form an activated complex, rather than by solubilizing the substrate.
    Saposin-B stimulates the hydrolysis of galacto-cerebroside sulfate by arylsulfatase A (EC 3.1.6.8), GM1 gangliosides by beta-galactosidase (EC 3.2.1.23) and globotriaosylceramide by alpha-galactosidase A (EC 3.2.1.22). Saposin-B forms a solubilizing complex with the substrates of the sphingolipid hydrolases.
    Saposin-D is a specific sphingomyelin phosphodiesterase activator (EC 3.1.4.12).
  • Involvement in diseaseDefects in PSAP are the cause of combined saposin deficiency (CSAPD) [MIM:611721]; also known as prosaposin deficiency. CSAPD is due to absence of all saposins, leading to a fatal storage disorder with hepatosplenomegaly and severe neurological involvement.
    Defects in PSAP saposin-B region are the cause of leukodystrophy metachromatic due to saposin-B deficiency (MLD-SAPB) [MIM:249900]. MLD-SAPB is an atypical form of metachromatic leukodystrophy. It is characterized by tissue accumulation of cerebroside-3-sulfate, demyelination, periventricular white matter abnormalities, peripheral neuropathy. Additional neurological features include dysarthria, ataxic gait, psychomotr regression, seizures, cognitive decline and spastic quadriparesis.
    Defects in PSAP saposin-C region are the cause of atypical Gaucher disease (AGD) [MIM:610539]. Affected individuals have marked glucosylceramide accumulation in the spleen without having a deficiency of glucosylceramide-beta glucosidase characteristic of classic Gaucher disease, a lysosomal storage disorder.
    Defects in PSAP saposin-A region are the cause of atypical Krabbe disease (AKRD) [MIM:611722]. AKRD is a disorder of galactosylceramide metabolism. AKRD features include progressive encephalopathy and abnormal myelination in the cerebral white matter resembling Krabbe disease.
    Note=Defects in PSAP saposin-D region are found in a variant of Tay-Sachs disease (GM2-gangliosidosis).
  • Sequence similaritiesContains 2 saposin A-type domains.
    Contains 4 saposin B-type domains.
  • Post-translational
    modifications
    This precursor is proteolytically processed to 4 small peptides, which are similar to each other and are sphingolipid hydrolase activator proteins.
    N-linked glycans show a high degree of microheterogeneity.
    The one residue extended Saposin-B-Val is only found in 5% of the chains.
  • Cellular localizationLysosome.
  • Information by UniProt

Recombinant Human PSAP protein images

  • The image shows an electrophoretic assay performed using an Agilent 5100 ALP. In some images coloured control bands can be seen at 15 kDa (green) and/or 240 kDa (purple). The protein-specific band is blue.

References for Recombinant Human PSAP protein (ab93982)

ab93982 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab93982.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"